MNTA  Momenta Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

1.07B

Vuru Grade

31.00/100

Current Price

$20.13
+0.04 (+0.20%)

Stability Price

$1.43
Overvalued by 92.90%

Company Metrics

  • 13.83 P/E
  • 20.5 P/S
  • 5.19 P/B
  • -1.91 EPS
  • -5.97% Cash ROIC
  • 8.05 Cash Ratio
  • 0 / 0% Dividend
  • 889,783.00 Avg. Vol.
  • 53.15M Shares
  • 1.07B Market Cap.

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Why Momenta Pharmaceuticals Inc. Shares Are Surging Higher
Motley Fool - Apr 16, 2015
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM ... - MarketWatch
Momenta Pharmaceuticals Inc. (MNTA) in Focus: Stock Jumps 6.1%
Zacks.com - Apr 17, 2015
Momenta Pharmaceuticals Inc. (MNTA - Analyst Report) was a big mover last session, as the company saw its shares rise over 6% on the day.
Momenta Pharmaceuticals Inc. (MNTA) in Focus: Stock Jumps 6.1% - Tale of the ... - Nasdaq
Will Momenta Pharmaceuticals (MNTA) Continue to Surge Higher?
Zacks.com - Apr 23, 2015
As of late, it has definitely been a great time to be an investor in Momenta Pharmaceuticals, Inc. (MNTA - Analyst Report).
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA FDA had approved Novartis ...
Inside Trade - Apr 21, 2015
(Motley Fool)Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares jumped by more than 10% earlier following news that the FDA had approved Novartis' (NYSE: NVS ) and Momenta's biosimilar to Teva Pharmaceuticals (NYSE: TEVA ) Copaxone.
Momenta Pharmaceuticals (MNTA) Showing Signs Of Perilous Reversal Today - TheStreet.com
Stock Analysts Update on Momenta Pharmaceuticals Inc (NASDAQ:MNTA) - Markets Wired
Why Momenta Pharmaceuticals, Inc. Jumped Higher Today
Motley Fool - Feb 19, 2015
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial ... - GlobeNewswire (press release)
Momenta Pharmaceuticals Inc. (MNTA) Jumps 7.89% on April 23
Equities.com - Apr 23, 2015
Momenta Pharmaceuticals Inc. (MNTA) was among the biggest gainers on the Russell 2000 for Thursday April 23 as the stock popped 7.89% to $20.09, representing a gain of $1.47 per share.
Momenta Pharmaceuticals, Inc. Pushes Forward
Motley Fool - Nov 5, 2014
At this point, earnings calls for Momenta Pharmaceuticals (NASDAQ: MNTA ) are more an opportunity to update investors than to report revenue and earnings.
Momenta Pharmaceuticals Reports Third Quarter 2014 Financial Results - MarketWatch
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q3 2014 Results ... - Seeking Alpha (registration)
Insider Selling: Ganesh Venkataraman Kaundinya Sells 34000 Shares of ...
sleekmoney - 11 minutes ago
Momenta Pharmaceuticals logo Momenta Pharmaceuticals (NASDAQ:MNTA) VP Ganesh Venkataraman Kaundinya sold 34,000 shares of the company's stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of ...
Insider Trade: Craig Wheeler Unloaded 6269 Shares of Momenta ...
OctaFinance.com - Apr 22, 2015
The President of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) 18.62 +0.56 3.10% , Craig Wheeler, has just sold - 6,269 shares of the firm he's leading - coming to an aggregate trade of $117,544 US Dollars (this based on share price of $18.8).
Momenta Pharmaceuticals Shares Down 4.9% Following Insider Selling (MNTA) - The Legacy
Momenta Pharmaceuticals SVP Sells $1032803.20 in Stock (MNTA) - sleekmoney
Zacks Rating Update On Momenta Pharmaceuticals, Inc.
Trade Journo - Apr 9, 2015
Momenta Pharmaceuticals (NASDAQ:MNTA) has received a short term rating of sell from research analysts at Zacks with a rank of 4. The company has been rated an average of 2 by 6 Wall Street Analysts. 4 analysts have added the counter in their list of ...